BLFS
NASDAQBioLife Solutions Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$27.20-0.16 (-0.58%)
01:30 PM07:45 PM
News · 26 weeks60-67%
2025-12-072026-05-31
Mix2190d
- Insider13(62%)
- SEC Filings4(19%)
- Other2(10%)
- Earnings2(10%)
Latest news
25 items- SECBioLife Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
- INSIDERLarge owner Casdin Partners Master Fund, L.P. sold $28,125,000 worth of shares (1,200,000 units at $23.44) (SEC Form 4)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- SECSEC Form 10-Q filed by BioLife Solutions Inc.10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
- SECBioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
- PRBioLife Solutions Reports First Quarter 2026 Financial ResultsTotal revenue of $27.5 million, up 25% over Q1 2025GAAP gross margin and non-GAAP adjusted gross margin of 64%GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenueConference call begins at 4:30 p.m. Eastern time todayBOTHELL, Wash., May 7, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2026. "We delivered a solid start
- SECAmendment: SEC Form 10-K/A filed by BioLife Solutions Inc.10-K/A - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
- PRBioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2026 first quarter financial results will be released on May 7, 2026. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relations page of the BioLife Solutions websit
- PRBioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCaseAward Recognizes Technologies That Address Important Industry Needs and Advance Prior StandardsBOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced it has received the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system purpose-built for frozen biologic materials. CellSeal CryoCase was developed in response to documented container failures in CGT manufacturing,
- INSIDERSEC Form 4 filed by Mathew Aby J.4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERSEC Form 4 filed by Berard Todd4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERSEC Form 4 filed by Wichterman Troy4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERSEC Form 4 filed by Foster Karen A.4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BioLife Solutions Inc.SCHEDULE 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
- INSIDERSEC Form 4 filed by De Greef Roderick4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERSEC Form 4 filed by Berard Todd4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERSEC Form 4 filed by Werner Sean4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERSEC Form 4 filed by Wichterman Troy4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERSEC Form 4 filed by Foster Karen A.4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERSEC Form 4 filed by Aebersold Sarah4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERSEC Form 4 filed by Mathew Aby J.4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Quality and Operations Foster Karen A. sold $1,962,998 worth of shares (97,423 units at $20.15), decreasing direct ownership by 46% to 113,242 units (SEC Form 4)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Technology Officer Werner Sean sold $2,302 worth of shares (111 units at $20.74), decreasing direct ownership by 0.22% to 49,932 units (SEC Form 4)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Quality and Operations Foster Karen A. sold $8,669 worth of shares (418 units at $20.74), decreasing direct ownership by 0.20% to 210,665 units (SEC Form 4)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mathew Aby J. sold $10,971 worth of shares (529 units at $20.74), decreasing direct ownership by 0.13% to 392,937 units (SEC Form 4)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
- INSIDERChief Financial Officer Wichterman Troy sold $12,195 worth of shares (588 units at $20.74), decreasing direct ownership by 0.27% to 220,649 units (SEC Form 4)4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
BLFS FAQ
6 questionsWhat does BioLife Solutions Inc. do?
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing...Where does BLFS stock trade?
BioLife Solutions Inc. (BLFS) is listed on NASDAQ.What sector and industry is BLFS in?
BioLife Solutions Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about BLFS?
BioLife Solutions Inc. has had 8 recent analyst actions on file. The most recent action was from Stephens: Overweight with a $3000.00 price target on 2025-07-22. Recent price targets range from $2200.00 to $3000.00.What companies are similar to BLFS?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare BLFS side-by-side with any of them on Quantisnow.How can I track BLFS on Quantisnow?
Quantisnow aggregates BioLife Solutions Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLFS to receive live email and push alerts on every new disclosure.